Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review

ConclusionReal-world studies reporting the economic impact of biosimilar NMS separately from drug costs are emerging, and those that reported such results found increased HRU in patients with biosimilar NMS. Studies of cost estimation have been largely limited to drug prices. Comprehensive evaluation of the economic impact of NMS should incorporate all important elements of healthcare service needs such as drug price, biologic rebates, HRU, NMS program setup, administration and monitoring costs.FundingAbbVie.

http://link.springer.com/10.1007/s12325-019-00998-3

Source: Advances in Therapy - June 4, 2019 Category: Drugs & Pharmacology Source Type: research